NCT02093403 - Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

November 26, 2016

Study Completion Date

November 26, 2016

Conditions

Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia

Interventions

DRUG

decitabine

Given IV

DRUG

selinexor

Given PO

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus